1
|
Rossetti P, Goldoni M, Pengo V, Vescovini R, Mozzoni P, Tassoni MI, Lombardi M, Rubino P, Bernuzzi G, Verzicco I, Manotti C, Quintavalla R. MiRNA 126 as a New Predictor Biomarker in Venous Thromboembolism of Persistent Residual Vein Obstruction: A Review of the Literature Plus a Pilot Study. Semin Thromb Hemost 2021; 47:982-991. [PMID: 34243207 DOI: 10.1055/s-0041-1726341] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
Venous thromboembolism (VTE) is the third most common cardiovascular disease. Interleukins (ILs) and micro-ribonucleic acids (miRNAs) have been proposed as molecules able to modulate endothelial inflammation and platelet hyperactivity. At present, no early biomarkers are available to predict the outcome of VTE. We investigated in a pilot study a selected number of miRNAs and ILs as prognostic VTE biomarkers and reviewed literature in this setting. Twenty-three patients (aged 18-65) with a new diagnosis of non-oncological VTE and free from chronic inflammatory diseases were enrolled. Twenty-three age- and sex-matched healthy blood donors were evaluated as control subjects. Serum miRNAs (MiRNA 126, 155, 17.92, 195), inflammatory cytokines (IL-6, tumor necrosis factor-α, IL-8), and lymphocyte subsets were evaluated in patients at enrolment (T0) and in controls. In VTE patients, clinical and instrumental follow-up were performed assessing residual vein obstruction, miRNA and ILs evaluation at 3 months' follow-up (T1). At T0, IL-8, activated T lymphocytes, Treg lymphocytes, and monocytes were higher in patients compared with healthy controls, as were miRNA 126 levels. Moreover, miRNA 126 and IL-6 were significantly increased at T0 compared with T1 evaluation in VTE patients. Higher levels of MiR126 at T0 correlated with a significant overall thrombotic residual at follow-up. In recent years an increasing number of studies (case-control studies, in vivo studies in animal models, in vitro studies) have suggested the potential role of miRNAs in modulating the cellular and biohumoral responses involved in VTE. In the frame of epidemiological evidence, this pilot study with a novel observational approach supports the notion that miRNA can be diagnostic biomarkers of VTE and first identifies miRNA 126 as a predictor of outcome, being associated with poor early recanalization.
Collapse
Affiliation(s)
- Pietro Rossetti
- Department of Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy
| | - Matteo Goldoni
- Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy
| | - Vittorio Pengo
- Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy
| | - Rosanna Vescovini
- Department of Clinical and Experimental Medicine, University Hospital of Parma, Parma, Italy
| | - Paola Mozzoni
- Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy
| | - Maria Ilaria Tassoni
- Department of Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy
| | - Maria Lombardi
- Department of Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy
| | - Pasquale Rubino
- Department of Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy
| | - Gino Bernuzzi
- Immunohematology and Transfusion Center, University Hospital of Parma, Parma, Italy
| | - Ignazio Verzicco
- Department of Clinical and Experimental Medicine, University Hospital of Parma, Parma, Italy
| | - Cesare Manotti
- Department of Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy
| | - Roberto Quintavalla
- Department of Internal Medicine, Angiology and Coagulation Unit, University Hospital of Parma, Parma, Italy
| |
Collapse
|
2
|
Pogliacomi F, Visigalli A, Valenti PG, Pedrazzini A, Bernuzzi G, Concari G, Vaienti E, Ceccarelli F. Rectus femoris myotendinous lesion treated with PRP: a case report. Acta Biomed 2019; 90:178-183. [PMID: 31821305 PMCID: PMC7233700 DOI: 10.23750/abm.v90i12-s.8932] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/14/2019] [Accepted: 10/14/2019] [Indexed: 01/02/2023]
Abstract
BACKGROUND AND AIM OF WORK Musculoskeletal injuries are the most common cause of severe, chronic pain and physical disability for the majority of all sport-related injuries. Platelet-rich plasma is being used more frequently to promote healing of muscle injuries. We report a case of 39 years old non professional soccer player who came to our attention for a quadriceps muscle pain onset after kicking the ball during a match. METHODS Clinical and instrumental evaluation revealed a myotendinous junction rupture of the rectus femoris with retraction of 1.5 cm from the anterior inferior iliac spine. We decided to treat the patient with PRP ultrasound guided injections and a specific rehabilitation protocol. RESULTS Clinical evaluation 45 days following the end of the treatment showed the resolution of the pain and the full recovery of strength and range of motion. Muscle healing was documented by magnetic resonance imaging. CONCLUSIONS Even if the role of PRP in muscle injury is not still clear, the result observed confirms that it could be used in the treatment of muscle lesions.
Collapse
Affiliation(s)
- Francesco Pogliacomi
- PARMA UNIVERSITY DEPARTMENT OF SURGICAL SCIENCES ORTHOPAEDIC AND TRAUMATOLOGY SECTION.
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Ingoglia F, Visigalli R, Rotoli BM, Barilli A, Riccardi B, Puccini P, Milioli M, Di Lascia M, Bernuzzi G, Dall’Asta V. Human macrophage differentiation induces OCTN2–mediated L-carnitine transport through stimulation of mTOR–STAT3 axis. J Leukoc Biol 2016; 101:665-674. [DOI: 10.1189/jlb.1a0616-254r] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2016] [Revised: 08/01/2016] [Accepted: 09/15/2016] [Indexed: 11/24/2022] Open
|
4
|
Raposio E, Bertozzi N, Bonomini S, Bernuzzi G, Formentini A, Grignaffini E, Pio Grieco M. Adipose-derived Stem Cells Added to Platelet-rich Plasma for Chronic Skin Ulcer Therapy. Wounds 2016; 28:126-131. [PMID: 27071140] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
INTRODUCTION Adipose-derived stem cells (ASCs) hold great promise for regenerative medicine applications due to their ability to promote the healing process through in situ differentiation and secretion of paracrine factor. The aim of this paper is to present a clinical adjunct for chronic skin wound therapy based on ASCs added to platelet-rich plasma (PRP), to obtain an enhanced PRP (e-PRP). MATERIALS AND METHODS For 18 months, 24 control-group patients with 31 chronic skin ulcers were treated with standard wound care, while 16 experimental-group patients with 21 chronic skin ulcers were treated with standard wound care and 1 e-PRP injection. The patients were randomly assigned to the control or experimental group. Outpatients had weekly follow-up visits where they were subjected to standard treatment and the wound healing process was assessed. RESULTS At the end of the study, the control and experimental groups had similar healing rates but wound closure rates were significantly different (P = 0.0257): 0.0890 cm(2) x day and 0.2287 cm(2) x day respectively, resulting in a faster recovery for the group treated with e-PRP. No side effects were reported. CONCLUSION In the authors' experience, e-PRP significantly enhanced wound closure rates when compared to standard wound care, without causing any serious complications. This finding highlights e-PRP as a valuable resource for chronic wound treatment.
Collapse
|
5
|
Ficarelli E, Bernuzzi G, Tognetti E, Bussolati O, Zucchi A, Adorni D, De Panfilis G. Treatment of chronic venous leg ulcers by platelet gel. Dermatol Ther 2008; 21 Suppl 1:S13-7. [DOI: 10.1111/j.1529-8019.2008.00196.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Elia GF, Magnani G, Belli L, Formentini A, Iacono S, Marchelli S, Pincolini S, Lecchini R, Bernuzzi G, Fiaccadori F. Incidence of anti-hepatitis C virus antibodies in non-A, non-B post-transfusion hepatitis in an area of northern Italy. Infection 1991; 19:336-9. [PMID: 1666064 DOI: 10.1007/bf01645359] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A total of 210 patients consecutively submitted to heart surgery at the Parma University Hospital and transfused with 1,898 units of blood were followed after transfusion in order to evaluate both the incidence of anti-hepatitis C virus (HCV) seroconversion in non-A, non-B post-transfusion hepatitis (PTH-NANB) cases and the usefulness of the screening for anti-HCV in comparison with that for serum glutamic pyruvic transaminase (SGPT) values in preventing PTH-NANB transmission. Fifteen recipients developed PTH-NANB (group A); ten of them (66.6%) showed anti-HCV seroconversion within 3-12 months. Eight of the ten anti-HCV positive patients developed chronic hepatitis, but none of the five PTH-NANB anti-HCV negative did. None of the 15 controls (group B) randomly chosen among the patient population showed anti-HCV seroconversion. A close correlation with the transmission of PTH was showed by anti-HCV positivity but not by SGPT elevation in blood donors. Eleven of 172 blood products transfused to group A but none of 139 products transfused to group B were anti-HCV positive. The incidence of elevated SGPT values was similar between the two groups of the transfused blood products. Nevertheless, the correlation observed between anti-HCV positivity and SGPT levels in the blood products involved in PTH confirms the need to exclude blood donors with abnormal SGPT values. On the whole, anti-HCV screening of donors showed a predictive value higher than that of SGPT (100% vs. 53.3%), allowing a minor blood donation exclusion.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- G F Elia
- Cattedra Malattie Infettive, Universita' di Parma, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|